Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech ConferenceCAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:30 p.m. ET in New York.
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTRCAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 12 – 15, 2025, in Honolulu, Hawaii.
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsMore Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 p.m. PT in San Francisco.
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingAll Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerCAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc.
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial LeaderCAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions.
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceCAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London.
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsInitial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual MeetingCAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company’s abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH).
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial ResultsU.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa)
Beam Therapeutics Announces Transition of Chief Financial OfficerCAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor.
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a Phase 1/2 clinical trial.
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell DiseaseMADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized, closed and automated manufacturing process for its base-edited CD34+ hematopoietic stem and progenitor cell (HSPC) genetic medicines in a poster presentation at the European Hematology Association (EHA) Hybrid Congress. The optimized process is deployed for the manufacturing of BEAM-101 in the BEACON Phase 1/2 clinical trial in patients with severe sickle cell disease (SCD), and the data include both preclinical and GMP clinical manufacturing experience to date.
Beam Therapeutics to Participate in Jefferies Global Healthcare ConferenceCAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president of Beam, plans to participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m. ET in New York City.
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressCAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Madrid, Spain on June 13-16, 2024.
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceCAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2024 Global Healthcare Conference on Wednesday, May 15, 2024, at 1:35 p.m. ET in New York City.
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsDosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated
MarketBeat Week in Review – 3/4 – 3/8The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hot
Beam Therapeutics Bolts Higher on Gene Therapy Licensing PaymentsBeam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Beam Therapeutics to Participate in Upcoming March 2024 Investor ConferencesCAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences:
Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage GainBeam Therapeutics Inc. (
NASDAQBEAM) is one of today’s top gainers. The company’s shares have moved 27.57% on the day to $45.67.
